Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database

✍ Scribed by Tristan D. Yan; Luis Zappa; Gary Edwards; Robert Alderman; Christina E. Marquardt; Paul H. Sugarbaker

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 196 KB
• Volume: 96
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.20736

✦ Synopsis

Abstract

Background

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy has expanded its application in the management of peritoneal carcinomatosis from gastrointestinal and ovarian malignancies. An accurate assessment of perioperative outcomes is crucial for integration of this combined procedure into clinical practice.

Methods

A prospective study of 80 patients undergoing the combined treatment for non‐appendiceal peritoneal carcinomatosis was conducted. Forty‐seven adverse events by eight organ‐systems were rated from Grade I to IV with increasing severity.

Results

One patient (1.3%) died postoperatively. Postoperative adverse events affected genitourinary system (38%), hematological system (31%), gastrointestinal system (25%), infection (20%), intravenous catheters status (15%), pulmonary system (14%), cardiovascular system (11%) and neurological system (4%). Thirty‐six patients (45%) experienced 49 Grade III adverse events. Six patients (8%) experienced eight Grade IV adverse events. More than four peritonectomy procedures (P = 0.010), and length of hospital stay of more than 21 days (P = 0.007) were strongly associated with Grade III and/or Grade IV morbidity.

Conclusion

The morbidity and mortality rates after the combined treatment for non‐appendiceal peritoneal carcinomatosis were within the acceptable range of surgical treatments for other gastrointestinal cancers. A standardized prospective database is required for an accurate assessment of perioperative outcomes. J. Surg. Oncol. 2007;96:102–112. © 2007 Wiley‐Liss, Inc.